--- title: "Let's talk more about DoveTree LLC. AI is so useful." type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/30999308.md" description: "$XTALPI(02228.HK) Direct to the results: 1 | DoveTree LLC's true background and current industry status. Notes: Established in Q4 2024, registered as an LLC in Massachusetts. First appeared in the news on 2025-06-23 in a collaboration announcement with PharmaTech Holdings (prnewswire.com). Positioning: Verdine Innovation Studio—integrating founder Gregory Verdine's research/capital network..." datetime: "2025-06-23T13:04:58.000Z" locales: - [en](https://longbridge.com/en/topics/30999308.md) - [zh-CN](https://longbridge.com/zh-CN/topics/30999308.md) - [zh-HK](https://longbridge.com/zh-HK/topics/30999308.md) author: "[老板的老板 AI Exec](https://longbridge.com/en/profiles/123.md)" --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/topics/30999308.md) | [繁體中文](https://longbridge.com/zh-HK/topics/30999308.md) # Let's talk more about DoveTree LLC. AI is so useful. $XTALPI(02228.HK) Direct to the results: ### 1 | The True Origins and Industry Position of DoveTree LLC Dimension Current Status Remarks **Establishment** 2024 Q4, registered as an LLC in Massachusetts State business records; first public appearance was in the collaboration announcement with XtalPi Holdings on 2025-06-23 ([prnewswire.com](https://www.prnewswire.com/apac/news-releases/xtalpi-announces-strategic-collaboration-with-harvard-professor-gregory-verdines-dovetree-llc-to-advance-novel-therapeutics-using-airobotics-drug-discovery-platform-302487822.html?utm_source=chatgpt.com)) **Positioning** _Verdine Innovation Studio_—Incubating novel mechanism therapies for oncology, autoimmune, and neurological diseases by integrating founder Gregory Verdine's scientific/capital network Similar to "platform incubators" like FogPharma but more focused on **target selection + early-stage architecture design** **Founder** **Gregory L. Verdine Ph.D.**• Tenured Professor of Chemistry at Harvard University (Erving Chair)• Founded/co-founded \>10 biotech companies, including Enanta, Wave, Aileron, etc., with ≥5 listed on U.S. markets• Directly associated with 3 FDA-approved drugs (romidepsin, paritaprevir, maviret series)• Since 2022, also an investment partner at **Andreessen Horowitz (a16z) Bio & Health** ([hscrb.harvard.edu](https://hscrb.harvard.edu/people/gregory-verdine/?utm_source=chatgpt.com), [ainvest.com](https://www.ainvest.com/news/xtalpi-10b-milestone-deal-dovetree-disruptive-play-drug-discovery-2506/?utm_source=chatgpt.com)) **Funding/Shareholders** No independent financing rounds disclosed yet; a16z and Verdine's VC vehicles (Larkspur, LifeMine SPV, etc.) are seen as potential cornerstones Industry reports ([biospectrumasia.com](https://www.biospectrumasia.com/news/26/26239/xtalpi-signs-billion-dollar-deal-with-dovetree-focusing-on-airobotics-drug-discovery-platform.html?utm_source=chatgpt.com)) **Pipeline** As of 2025-06, no proprietary IND projects; opted to collaborate with external AI-Physics platforms to rapidly fill the pipeline via "agreements + milestones" The contract with XtalPi is the first publicly announced project > **Industry Position Summary**: DoveTree itself is still in the "_company-builder_/project shell" phase, lacking traditional R&D capabilities; its influence stems from Verdine's academic reputation + serial entrepreneurial success, as well as a16z's robust financing/BD channels. This is believed to be sufficient for early-stage innovation projects to quickly secure funding and resources, but DoveTree still relies on external technology platforms (e.g., XtalPi) for heavy experimental work. * * * ### 2 | The Long-Term Implications of the Announcement Terms for XtalPi (02228) Dimension Details (from the Announcement) Long-Term Value Risk Factors **Immediate Cash Flow** Upfront payment of **$100 million** ($51 million within 10 days + $49 million within 180 days) ([prnewswire.com](https://www.prnewswire.com/apac/news-releases/xtalpi-announces-strategic-collaboration-with-harvard-professor-gregory-verdines-dovetree-llc-to-advance-novel-therapeutics-using-airobotics-drug-discovery-platform-302487822.html?utm_source=chatgpt.com)) Equivalent to 1.3× XtalPi's 2023 annual revenue → Can support subsequent robotics lab expansion and overseas BD The contract is still a _non-binding term-sheet_; delays or reductions in the final agreement could impact recognition **Milestones & Royalties** Development + sales milestones capped at "billions of dollars" + single-digit sales royalties If 1-2 pipelines reach late-stage, XtalPi could generate high-leverage _royalty_ streams, significantly boosting valuation flexibility AI early hit→clinical success rate <8%; high-value milestones are often unmet **Technical Validation** Projects include both **small molecules and antibodies** First time XtalPi's _AI + robotics_ capabilities extend to antibody discovery; successful delivery could correct the perception of "only excelling in small molecules" Antibody workflows demand higher wet-lab and CMC requirements, increasing delivery pressure **North American Channels** Verdine + a16z endorsement Establishes a "trust bridge" for XtalPi in the Boston-Cambridge biotech circle, facilitating more U.S.-based BD contracts Profitability still depends on actual delivery to solidify reputation **Valuation Anchor** Comparable in upfront payment scale to AI-Big Pharma frameworks like Recursion-Roche and Exscientia-Sanofi Boosts the "platform-type AI Drug-Discovery" valuation multiple in the Hong Kong secondary market; a strong bargaining chip for future U.S. or STAR Market refinancing Limited liquidity in Hong Kong; realizing valuation requires sustained performance * * * ### 3 | Scenario Analysis **Optimistic Path** _2025-2027_: First batch of targets yields leads within 18 months; DoveTree completes Series A+B, XtalPi receives 1-2 early milestone payments; 2028-2029 sees 1 IND enter Phase I → XtalPi confirms ≥$300 million in development milestones → Stock price and revenue rise. **Baseline Path** _After upfront payment_, earliest milestones take 24-30 months; if key drugability metrics are unmet, milestones are delayed, limiting discounted future revenue impact. However, technical validation can still be leveraged for next-client BD. **Pessimistic Path** DoveTree postpones Definitive Agreement due to financing market shifts or weak asset performance → Project termination; XtalPi may need to refund partial payments or only recognize break-up fees, dampening market sentiment. * * * ## Conclusion **DoveTree LLC** → Not a traditional pharma giant but a **"project incubator + investment"** platform newly built by Gregory Verdine with a16z resources; influence primarily derives from the founder's academic and entrepreneurial reputation. For **XtalPi**, this term-sheet carries triple significance: **major cash infusion + brand endorsement + technical expansion validation**. If executed smoothly, it could elevate XtalPi from an "AI small-molecule service provider" to an industry benchmark for "multi-modal AI-robotics drug factories." However, the deal has yet to be finalized, clinical milestones have long cycles, and execution/financing uncertainties require ongoing attention. ### Related Stocks - [XTALPI (02228.HK)](https://longbridge.com/en/quote/02228.HK.md) ## Comments (5) - **John_Tang · 2025-06-23T22:35:06.000Z**: t h x - **lukcy千炫948888 · 2025-06-23T19:53:51.000Z**: Thank you, boss - **江汉南京 · 2025-06-23T13:46:05.000Z**: Thank you, boss. Appreciate the sharing. - **了不起的不凡 · 2025-06-23T13:11:31.000Z**: Thanks for sharing 🥹 - **wolf-001 · 2025-06-23T13:08:02.000Z**: good